BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that virtually the same percentage of surveyed rheumatologists selected Amgen/Pfizer/Takeda’s Enbrel (43 percent) and Abbott/Eisai’s Humira (42 percent) as the most efficacious agent for the treatment of rheumatoid arthritis. The shrinking gap in the percentage of surveyed rheumatologists who favor Enbrel over Humira in terms of efficacy suggests that Humira is threatening Enbrel’s sales-leading position in rheumatoid arthritis. Nevertheless, physicians continue to regard Enbrel as the agent with the best overall clinical profile, owing to the strength of its perceived safety and tolerability advantages over Humira.
